News

AAO, Surgical Care Coalition teaming up to ensure the final version of the rule is fair to ophthalmologists and surgeons as one company is expressing its disappointment in the proposal.

Nanoscope Therapeutics Inc. has dosed its first patient in a late-stage Phase 2b trial of a gene therapy that delivers multi-characteristic opsin to retinal cells.

The Gilbert Family Foundation is collaborating with the Children’s Oncology Group and Children’s Hospital of Philadelphia to validate a tool to measure progressive vision loss.

According to iSTAR Medical, the STAR-V study will investigate the device in 350 patients with primary open angle glaucoma.

Alkeus Pharmaceuticals, Inc, announced Thursday that the FDA has granted Breakthrough Therapy Designation (BTS) for ALK-001 (C20-D3-vitamin A) for the treatment of Stargardt disease.

Usher syndrome 1G protein SANS regulates the splicing of genes, particularly those linked to Usher syndrome, which can lead to early vision loss form RP.

The company, formerly called BELKIN Laser, announced Thursday that it will begin operating under the new name BELKIN Vision.

Physicians in India have reported 7,200 documented cases of mucormycosis infections in patients with severe COVID-19 infections.

ASCRS has issued a statement calling on Aetna to drop a new prior authorization policy it implemented last week that delays cataract surgeries.

The American Medical Association recently announced policies adopted by physician and medical student leaders from all corners of medicine on the final day of the Special Meeting of the AMA House of Delegates.

In an observational study, investigators are looking at the role of antibody secreting plasmablasts and GC B cells induced by the COVID-19 vaccines.

MedShr Insights has developed an early warning system that applies natural language processing, artificial intelligence, and machine learnings.

The company’s IASAB will identify key business initiatives, ensuring they align with its strategic vision.

AAO develops task forces to evaluate academy, review outcomes in ophthalmology.

Santen Inc. announced Thursday that the U.S. FDA has approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops to treat vernal keratoconjunctivitis (VKC).

If approved, PDS ranibizumab would become the first and only eye implant with continuous drug delivery offering people with wet AMD.

According to investigators, the system has been shown to almost triple the number of people with eye problems attending primary care, as well as increasing appropriate uptake of hospital services.

Postop management with long-term topical antibiotics is critical to successful device retention.

Oyster Point Pharma announced today the enrollment of the first participant in its OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray to treat stage 1 neurotrophic keratopathy (NK).

Implandata received FDA Breakthrough Device Designation for its Eyemate-SC in April and now has CE Mark approval in the European Union.

The American Medical Association is advocating equitable resource distribution of vaccinations to assist low-income countries.

According to investigators, infants may have an edge over adults, with babies demonstrating a stronger immune response to the SARS-CoV-2 virus.

According to investigators, the new technology is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.

The US Supreme Court ruled Thursday that the Affordable Care Act remains valid, rejecting a claim by several states that a recent change to the law made it unconstitutional.

The event, being held at the Mandalay Bay Resort and Casino in Las Vegas, is offering a full agenda for in-person attendees.

The American Academy of Ophthalmology is calling on its members to continue to build confidence in COVID-19 vaccines and encourage people to get vaccinated, including their staff.

Clearside Biomedical, Inc. reported today positive safety results from Cohort 1 of its ongoing OASIS phase1/2a clinical trial of CLS-AX for the treatment of wet AMD.

Classification criteria funded by the National Institutes of Health will facilitate clinical research for new therapies.